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The Pathway to Melanosomes 
Melanosomes are organelles unique to pigment-producing cells. 
Their biogenesis encompasses four stages, identified by differential 
density gradient separation and electronmicroscopy. "Premelano-
somes" (stage I) arise from the trans-Golgi network (TGN) as spher-
ical vacuoles with an ill-defined matrix. In Stage II, they become 
elliptical and develop matrix. Other vesicles originating in t~e 
TGN contain tyrosinase, the enzyme that catalyzes three steps 111 
melanogenesis. Fusion of these vesicles with stage II melanosomes 
allows the initiation of pigment formation. Stage III and IV melano-
somes represent vesicles containing increasing amounts of melanin. 
The relationship between formation of melanosomes and lysosomes 
has been postulated for many years based on several indirect obser-
vations. Acid phosphatase is found in both lysosomes and melano-
somes, genetic lesions in mice and humans coordinately disrupt 
functions in elements of both systems, and chloroquine, which is 
targeted to lysosomes, causes hypopigmentation of skin and hair, 
Further, coated vesicles from melanoma cells contain high levels of 
three enzymes and two precursors of melanogenesis. 
Seth Orlow and his co-workers studied the origin of this very 
specialized pathway and its possible derivation from more com-
monly found vesicle-mediated systems. In the November issue of 
the Journal, Orlow et aJ showed that both tyrosinase and tyrosinase-
related protein (TRP-l) appear in early melanosomes with sparse or 
mutant melanin formation. Only tyrosinase is found in heavily 
pigmented melanosomes. A lysosome-associated membrane protein 
(LAMP-1) overlaps the distribution ofTRP-1, but was not found in 
melanin-ricl~ melanosomes. In. this issue, these investigators use 
antiserum directed aga1l1st punfied melanoma coated vesicles to 
investigate the relationship between the membrane glycoproteins 
of lysosomes and melanosomes. This antibody recognized two 
major glycoprote1l1s: band 1(47 - 55 kDa) is specific to melanocytes 
and band II (90-120 kDa) is present in all tissues. Immunolocaliza-
tion of the v.esicle-speci~c antibody is primarily to early melano-
somes, even III b&hly pigmented cells. Western analysis, co-sedi-
mentation, and Immunocompetition studies with antibodies 
d~rected against ~AMP-1 confirm that this glycoprotein is the ubiq-
Uitous coated veSicle band II and provide further evidence of shared 
organelle li.neage. Analysis of these shared Iysosomaljmelanosomal 
protellls Will be a key to understanding genetic disorders such as 
Chediak-Higashi syndrome in humans or many of the recessive 
mutations of coat color and ocular pigmentation in mice. 
Dermatofibrosarcoma Protuberans: X Marks the Clonal Analysis 
Skin cancers, and carcinomas in general, are most often of epithelial 
origin. They arise from somatic cell DNA mutation in response to 
environmental assaults, followed by clonal proliferation. Malig-
nantly transformed cells have lost their normal mechanism for 
growth control by activation of a growth-stimulating oncogene or 
the loss or inactivation of a tumor-suppressor function. Tumors of 
mesenchymal elements, such as dermatofibrosarcoma protuberans 
(DFSP), are rare and produce neoplasms that are seldom metastatic. 
They are locally aggressive and invasive and will regrow unless they 
are removed completely by surgery. 
What is the nature of these tumors? What causes their loss of 
growth control? Do they represent monoclonal expansion of malig-
nant transformation or polyclonal disordered growth resulting from 
abnormal stimulation by inducers? Little is known about the molec-
ular pathology ofDFSP, except that it occurs much more frequently 
in men and cytogenetic studies show some chromosomal heteroge-
neiry in cultured tumor cell populations . 
In this issue Monica Peacocke and her group have determined the 
clonal characteristics of DFSP elegantly by combining modern ge-
netic tools. Although this condition is more prevalent in men, two 
female patients with characteristic DFSP came to their attention. 
~UI.nan ~emales have ~0?C chromosomes that are often genetically 
dlstlllgUishable by restnctlon enzyme an.alysis. At an early age dur-
IIlg development, o~e X chrom~s0r.n~ IS randomly inactivated in 
each cell, result1l1g 111 an adult mdlvldual that is mosaic for the 
functioning x chromos?me. Activ~ly transcribed genes often have 
methylated cytosme reSidues m their control regions. This modifica-
tion .prev~nts th~ cleavage of DNA by some restriction enzymes, 
an~ Identifies active genes. Southern analysis, probing for a consti-
tutively expressed X chromosome gene, will produce two "bands" 
in a random ~ell population or a polyclonal tumor. Only one " band" 
IS detected m DNA from cells that are monoclonal. This study 
compares DNA from normal dermal fibroblasts and tumors of 
DFSP patients. Both X chromosomes are active in the normal fi-
broblast controls. However, a single X chromosome is active in each 
of the tumor populations, indicating that the tumors are of clonal 
origin. 
CD44 Expression and Melanoma Migration 
When tumor cells invade, they require attachment molecules to 
pull themselves toward the vasculature and metastasize. These mole-
cules must provide both a physical attachment to generate tension, 
and a signaling mechanism to activate the contractile elements of 
the cell. The cel~ surface glycoprotein, CD44, is found on many 
types of ce.lls and mteracts with glycosaminoglycans of the extracel-
lu!ar ma~nx (ECM). It also has a cytoplasmic domain that associates 
With actin. Lymphoma cells expressing transfected human CD44 
0022-202X/93/S06.00 Copyright © 1993 by The Society for Investigative Dermatology, Inc. 
97 
98 IN THIS ISSUE 
become invasive and rodent CD44 causes metastasis of epithelial 
tumOr cell lines. T here is heterogeneous expression of CD44 in 
melanoma, and different melanomas show varied levels of invasive-
ness. However, there seems to be a correlation of the level of hyal-
uronic acid synthesized and deposited in highly invasive murine 
melanomas. 
Byers and his co-workers have used time-lapse video-microscopy 
to measure the rate of cellular migration as a function of 1) the level 
of CD44 expressed by different melanomas and 2) the nature of the 
cell culture substratum. Cells with high levels of immunoreactive 
CD44 showed a marked dose-dependent increase in migration rates 
on hyaluronate. Cells expressing low levels of CD44 did not re-
spond to hyaluronate. N o cells were stimulated to become more 
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motile by chondroitin-6-sulfate substrata. This specific response 
was blocked either by addition of soluble receptor (CD44 receptor 
globulin) or molecules that bind to CD44. Hyaluronate-coated po-
lycarbonate membranes also stimulated hap to tactic invasiveness of 
the CD44(+) melanomas, but not the CD44(-) cell lines. These 
authors have concurrently published a study in which CD44(-) 
cells exhibit enhanced migration on hyaluronate after expression of 
transfected CD44. This work provides a convincing in lIitro demon-
stration of the importance of CD44 expression and the presence of 
attached hyaluronate in invasive migration of melanomas. Manipu-
lation of these molecules in lIillo may be useful in the treatment of 
melanoma. 
. . . and Briefly 
A retrospective study of Austrian patients initially examined for 
cutaneous symptoms of Lyme disease compared methods of treat-
ment and later complications using immunodiagnostic tests for IgG 
and IgM Borrelia burgdorferi antibodies. Whereas this disorder is 
relatively new to the United States, its manifestations have been 
observed in Europe for over 60 years. One major problem with 
treatment of Lyme disease is its clinical spectrum. This report 
demonstrates that none of the serotesting employed was conclusive 
for late stage disease, nor did the results correlate well with 
time of diagnosis or mode of treatment. It further points out 
that there may be a substantial geographical spectrum for this dis-
ease. 
